NCE Discovery and Domainex merge to create a new drug discovery company

12-Jul-2007

Domainex Ltd and NCE Discovery Ltd merged to form a new drug discovery company focused on nucleotide triphosphate (NTP)-dependent proteins. The parent company will be known as Domainex, and it will offer access to its technology platform on a 'fee for service' basis through its service division, which will trade as NCE Discovery.

The new company combines NCED's expertise in medicinal chemistry with Domainex's innovative Combinatorial Domain Hunting (CDH) technique for producing recombinant proteins, forming a well-rounded platform for novel drug discovery. Domainex will apply this powerful combination of structural biology and medicinal chemistry approaches to the development of small-molecule drugs with activity against key NTP-dependent protein targets.

Both NCE Discovery and Domainex are spinout companies from University College London (UCL) which, via UCL Cruciform Ltd, is a major shareholder of NCE Discovery and holds shares directly in Domainex. Domainex is also a spinout of the Institute of Cancer Research and Birkbeck College London. UCL Business plc (UCLB), a wholly owned subsidiary of UCL, has also become an investor in the new merged company.

https://www.bionity.com/en/news/66166/nce-discovery-and-domainex-merge-to-create-a-new-drug-discovery-company.html